Adam Marťák

Adam Marťák, founder and CEO of ambiom—a life science advisory firm in Bratislava—shares insights into Eastern Europe's biotech scene. He discusses the challenges startups face, from navigating complex regulations to securing funding. Marťák explains different biotech valuation methods, emphasizing that early-stage companies offer greater upside potential for investors. The conversation also explores how pipeline composition affects success rates and touches on the increasing influence of AI in drug discovery, transforming the investment landscape.